Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into antibody therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai. Aducanumab is a human monoclonal antibody removing beta amyloid in brains of pat...
Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into antibody therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune collaborates on aducanumab with Biogen who co-develops it with Eisai. Aducanumab is a human monoclonal antibody removing beta amyloid in brains of patients with Alzheimer’s disease. Based on large Phase 3 study results showing clinical benefit, Biogen plans regulatory filing for aducanumab in Alzheimer’s disease.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.